VASOPRESSOR THERAPY OF HEPATORENAL SYNDROME AGAINST THE BACKGROUND OF ALCOHOLIC LIVER CIRRHOSIS

Authors:

Abstract:

Hepatorenal syndrome is one of the most common causes of death in liver cirrhosis, and its treatment methods are insufficiently studied, therefore, the aim of this study was to compare the effectiveness of different schemes of vasopressor therapy. A total of 109 patients with alcoholic liver cirrhosis were divided into two groups: group 1 (n=57) – received terlipressin+albumin, group 2 (n=52) – midodrine+octreotide+albumin. According to the study results, there was a significant difference in the cumulative 3–month survival in groups 1 and 2 (56.1 % vs. 28.8 %, p˂0.05). In the multivariate analysis, only the complete response to treatment (risk ratio – 23.92; p˂0.002) and the initial severity scores (risk ratio – 1.18; p˂0.02) were predictors of 3–month survival. Terlipressin showed greater therapeutic efficacy, as it reduced mortality risk by 3.65 times (from 0.558±0.034 to 0.153±0.026) (p<0.05) and improved renal function (70.2 % in group 1 versus 28.8 % – in group 2) (p=0.01).

Keywords:

hepatorenal syndrome alcoholic liver cirrhosis terlipressin vasopressors

References:

1. Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Semin Nephrol. 2019; 39(1):17–30. doi: 10.1016/j.semnephrol.2018.10.002.
2. Angeli P, Garcia–Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019; 71(4):811–822. doi: 10.1016/j.jhep.2019.07.002.
3. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al.; REVERSE Study Investigators. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterol. 2016; 150(7):1579–1589.e2. doi: 10.1053/j.gastro.2016.02.026.
4. Davenport A, Sheikh MF, Lamb E, Agarwal B, Jalan R. Acute kidney injury in acute–on–chronic liver failure: where does hepatorenal syndrome fit? Kidney Intern. 2017; 92(5):1058–1070. doi: 10.1016/j.kint.2017.04.048.
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2018; 53(3):397–417.doi: 10.1016/j.jhep.2010.05.004.
6. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal Syndrome. Clin J Am SocNephrol. 2019; 14(5):774–781. doi: 10.2215/CJN.12451018.
7. Kim MY, Seo YS. Acute Kidney Injury and Hepatorenal Syndrome. Korean J Gastroenterol. 2018; 72(2):64–73. doi: 10.4166/kjg.2018.72.2.64.
8. Mattos ÂZ, Schacher FC, Mattos AA. Vasoconstrictors in hepatorenal syndrome – A critical review. Ann Hepatol. 2019; 18(2):287–290. doi: 10.1016/j.aohep.2018.12.002.
9. Mindikoglu AL, PappasSC. New Developments in Hepatorenal Syndrome. Clin GastroenterolHepatol. 2018; 16(2):162–177.e1. doi: 10.1016/j.cgh.2017.05.041.
10. Nguyen–Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. Un Eur Gastroenterol J. 2019; 7(4):529–537. doi: 10.1177/2050640619825719.
11. Ray K. Searching for therapies for advanced cirrhosis. Nat Rev Gastroenterol Hepatol. 2021; 18(5):286. doi: 10.1038/s41575–021–00442–4.
12. Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT–0401 and REVERSE randomised clinical studies. Alim Pharmacol Ther. 2017; 45(11):1390–1402. doi: 10.1111/apt.14052.
13. Sharma P, Moore K, Ganger D, Grewal P, Brown RS. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. J Liver Transpl. 2020; 26(10):1328–1336. doi: 10.1002/lt.25834.
14. Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol. 2020; 16(3):137–155. doi: 10.1038/s41581–019–0218–4.
15. Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, et al.; CONFIRM Study Investigators. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. New Engl J Med. 2021; 384(9):818–828. doi: 10.1056/NEJMoa2008290.

Publication:

«World of Medicine and Biology» Vol. 17 No. 77 (2021) , с. 158-162
УДК 616.36–06:616.61]–008.64–07–085.225.1:616.36–004

DOI:

https://doi.org/10.26724/2079-8334-2021-3-77-158-162